<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02839460</url>
  </required_header>
  <id_info>
    <org_study_id>TWEAK</org_study_id>
    <nct_id>NCT02839460</nct_id>
  </id_info>
  <brief_title>A Prospective Study Of Biomarkers Of Skeletal Muscle Atrophy</brief_title>
  <acronym>TWEAK</acronym>
  <official_title>A Single-Center, Prospective Study to Evaluate Biomarkers of Skeletal Muscle Atrophy in Sarcopenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center, prospective biomarker study to evaluate serum levels of TWEAK and
      expression levels of TWEAK and Fn14 in muscle biopsies from patients with sarcopenia as well
      as healthy, physically active controls.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Serum concentration of TWEAK at day 1</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relative expression levels of TWEAK mRNA in muscle biopsy at day 1</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative expression levels of Fn14 mRNA in muscle biopsy at day 1</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between serum TWEAK levels and muscle strength</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of AEs and SAEs</measure>
    <time_frame>Screening through Day 14</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Sarcopenia</condition>
  <arm_group>
    <arm_group_label>subjects with sarcopenia</arm_group_label>
    <description>Screening Procedures (Physical Exam, Height &amp; Weight, Vitals, Medical History, CHAMPS, DXA Scan, Physical Performance Testing, Muscle Strength Testing, Blood Collection)
Day 1 (target +/- 2 days) Outpatient Muscle Biopsy (Vitals, Blood Collection, Muscle Biopsy, update Concomitant Therapy and Procedure-Related AEs/SAEs)
Day 14 (target +/- 2 days) Safety Follow-up Visit (Vitals, Blood Collection, update Concomitant Therapy and Procedure-Related AEs/SAEs)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy, physically-active controls</arm_group_label>
    <description>Screening Procedures (Physical Exam, Height &amp; Weight, Vitals, Medical History, CHAMPS, DXA Scan, Physical Performance Testing, Muscle Strength Testing, Blood Collection)
Day 1 (target +/- 2 days) Outpatient Muscle Biopsy (Vitals, Blood Collection, Muscle Biopsy, update Concomitant Therapy and Procedure-Related AEs/SAEs)
Day 14 (target +/- 2 days) Safety Follow-up Visit (Vitals, Blood Collection, update Concomitant Therapy and Procedure-Related AEs/SAEs)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Outpatient Muscle Biopsy</intervention_name>
    <description>Outpatient Muscle Biopsy involving skeletal muscle sample collected from the vastus lateralis muscle</description>
    <arm_group_label>subjects with sarcopenia</arm_group_label>
    <arm_group_label>healthy, physically-active controls</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Muscle biopsy samples may be retained for mRNA analysis
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects over age 65 Subjects with Sarcopenia Subjects who are healthy, physically-active
        controls
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        To be eligible to participate in this study, all candidates must meet the following
        eligibility criteria at Baseline or at the time point specified in the individual
        eligibility criterion listed:

        All Participants

        1. Ability to understand the purpose and risks of the study and provide signed and dated
        informed consent and authorization to use protected health information in accordance with
        national and local subject privacy regulations

        Subjects with Sarcopenia

          1. Men and postmenopausal women of 65 years of age or older

          2. Gait speed measured over 4 meters of &lt;1.0 m/s OR grip strength &lt; 26 kg for men or &lt; 16
             kg for women.

          3. Appendicular skeletal muscle adjusted for BMI by DXA ≤ 0.789 for men and ≤ 0.512 for
             women.

          4. Weigh at least 40kg;

          5. Self-reported difficulty climbing 10 steps OR walking outside on level ground for 1/4
             mile

        Healthy Controls

          1. Men and postmenopausal women of 65 Years of age or older

          2. Body mass index (BMI) between 18.5 and 30 kg/m2 inclusive at the time of Screening

          3. Measures of Physical Performance and Lean Mass exceed thresholds defined for
             Sarcopenia group.

          4. ≥ 150 minutes/week moderate-intensity physical activity OR regular engagement in
             resistance training ≥ 2 days/week

          5. Willing to maintain a consistent diet and pattern of physical activity for the
             duration of the study

        Exclusion Criteria:

        Candidates will be excluded from study entry if any of the following exclusion criteria
        exist at Screening:

          1. History of human immunodeficiency virus (HIV), hepatitis B or C, or tuberculosis (TB)

          2. Immunocompromized subjects, as determined by the Investigator, based on medical
             history, physical examination, or laboratory testing, or due to prior or current
             immunosuppressive or immunomodulating treatment, including, but not limited to, HIV
             infection, history of organ transplantation, and anti-rejection therapy

          3. Acute infection (urinary, respiratory, other) within past week or hospitalization
             within one month

          4. Participation in any interventional clinical study within 12 weeks

          5. A lower limb fracture in the past 6 months or any impairment or disease severely
             affecting gait (e.g. stroke with hemiparesis, myasthenia gravis, Parkinson's disease,
             peripheral polyneuropathy, intermittent claudication in advanced peripheral vascular
             disease, spinal stenosis, or severe osteoarthritis of the knee or hip);

          6. Any underlying muscle disease including active myopathy or muscular dystrophy.

          7. Confirmed diagnosis of heart failure classified as New York Heart Association Class
             III and IV (e.g. cardiomyopathy) or hypertrophic cardiomyopathy.

          8. Type I diabetes or uncontrolled Type 2 diabetes (HA1C ≥ 9).

          9. Requires regular assistance from another person for general activities of daily living
             (e.g. bathing, dressing)

         10. Moderate to Vigorous Exercise performed in week prior to study visits (temporary
             exclusion - will be rescheduled)

         11. Any other condition judged by the Principal Investigator or Study Physician to
             preclude safe participation in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen D Anton, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephen D Anton, PhD</last_name>
    <phone>(352) 294-5800</phone>
  </overall_contact>
  <location>
    <facility>
      <name>University of Florida Institute on Aging</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annie M Allen, MBA</last_name>
      <phone>352-294-5800</phone>
      <email>asmithbova@ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Stephen D Anton, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2016</study_first_submitted>
  <study_first_submitted_qc>July 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2016</study_first_posted>
  <last_update_submitted>April 9, 2018</last_update_submitted>
  <last_update_submitted_qc>April 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrophy</mesh_term>
    <mesh_term>Sarcopenia</mesh_term>
    <mesh_term>Muscular Atrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

